Comparative Pharmacology
Head-to-head clinical analysis: ASBRON versus CHOLEDYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASBRON versus CHOLEDYL.
ASBRON vs CHOLEDYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.
Choledyl is a salt of theophylline (1,3-dimethylxanthine) and choline. Theophylline acts as a bronchodilator by inhibiting phosphodiesterase (PDE) and antagonizing adenosine receptors, resulting in increased intracellular cAMP and smooth muscle relaxation. It also enhances respiratory drive and diaphragm contractility.
1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.
200-400 mg orally 4 times daily, not to exceed 2.4 g/day; or as sustained-release tablets: 400-600 mg twice daily.
None Documented
None Documented
4-6 hours in adults; prolonged to 8-12 hours in hepatic impairment or elderly patients
Terminal elimination half-life: 7-9 hours (non-smoking adults); 4-5 hours (smokers); 20-30 hours (premature neonates, hepatic cirrhosis, CHF); clinical context: dose adjustment required for smokers and hepatic impairment.
Primarily renal (70-80% as unchanged drug), biliary/fecal (~15-20% as metabolites and unchanged drug)
Primarily renal excretion of theophylline metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid), with 10% unchanged drug; biliary/fecal < 5%.
Category C
Category C
Bronchodilator
Bronchodilator